Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Deals  ·  Weekly Digest - 21 March to 27 March 2026
Tempus announces strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation across an ADC clinical program

Weekly Digest – March 2026 Weekly Digest – March 2026 25 March 2026: Tempus announces strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation across an ADC clinical program Tempus has entered into a strategic collaboration […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 21 March to 27 March 2026
GlycoNex Inc. and Nippon Kayaku Co., Ltd. enter collaboration to advance next-generation ADC candidate GNX201-ADC

Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: GlycoNex Inc. and Nippon Kayaku Co., Ltd. enter collaboration to advance next-generation ADC candidate GNX201-ADC GlycoNex and Nippon Kayaku have entered into a strategic collaboration to advance […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 14 March to 20 March 2026
Alphamab Oncology announces IND application for innovative EGFR/HER3 dual payload bispecific ADC JSKN021 was officially accepted by CDE

Weekly Digest – March 2026 Weekly Digest – March 2026 13 March 2026: Alphamab Oncology announces IND application for innovative EGFR/HER3 dual payload bispecific ADC JSKN021 was officially accepted by CDE Alphamab Oncology has achieved a key regulatory milestone, as […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 14 March to 20 March 2026
Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative breast cancer of TROP2/HER3 bispecific ADC JSKN016

Weekly Digest – March 2026 Weekly Digest – March 2026 20 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative breast cancer of TROP2/HER3 bispecific ADC JSKN016 Alphamab Oncology has reached a […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 14 March to 20 March 2026
CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer

Weekly Digest – March 2026 Weekly Digest – March 2026 16 March 2026: CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer CytomX Therapeutics has strengthened its position in next-generation […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 14 March to 20 March 2026
Alphamab Oncology announces the first patient dosed in a Phase 1 clinical study of PD-L1/VEGFR2 bispecific ADC JSKN027

Weekly Digest – March 2026 Weekly Digest – March 2026 17 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 1 clinical study of PD-L1/VEGFR2 bispecific ADC JSKN027 Alphamab Oncology continues to expand its ADC pipeline, announcing […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 14 March to 20 March 2026
Voro Therapeutics announced research collaboration with Daiichi Sankyo to advance PrimeBody™ technology for next-generation tumor-activated ADCs

Weekly Digest – March 2026 Weekly Digest – March 2026 17 March 2026: Voro Therapeutics announced research collaboration with Daiichi Sankyo to advance PrimeBody™ technology for next-generation tumor-activated ADCs Voro Therapeutics has entered a strategic research collaboration with Daiichi Sankyo, […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 14 March to 20 March 2026
Aptamer Group initiated Optimer radiopharmaceutical programme with Radiopharmium Ltd

Weekly Digest – March 2026 Weekly Digest – March 2026 18 March 2026: Aptamer Group initiated Optimer radiopharmaceutical programme with Radiopharmium Ltd Aptamer Group plc has officially entered the fast-growing radiopharmaceutical space, launching a targeted programme built around its Optimer […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 07 March to 13 March 2026
Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

Weekly Digest – March 2026 Weekly Digest – March 2026 9 March 2026: Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer AstraZeneca and Daiichi Sankyo announced that the U.S. FDA has […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 07 March to 13 March 2026
Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Weekly Digest – March 2026 Weekly Digest – March 2026 09 March 2026: Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma Oncopeptides announced that it has secured fast-track designation in Norway for a planned Window-of-Opportunity clinical study evaluating a […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous181920212223242526Next ›Last »
Page 22 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id